Corporate Banner
Satellite Banner
Crystallography
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Calixar and Synthelis Team Up to Provide Unique Membrane Protein Services

Published: Friday, July 06, 2012
Last Updated: Thursday, July 05, 2012
Bookmark and Share
Partnership will enable life sciences researchers and industry to access a comprehensive and innovative range of services to obtain currently unavailable therapeutic targets.

Calixar has announced that they have entered into an alliance for the production and isolation of all types of target membrane proteins.

The results of this collaboration will have applications ranging from the development of antibodies to the discovery of new drugs, including the determination of the structure of these targets and vaccine formulations.

Instead of trying to produce these proteins themselves, users will be given access to production and purification technologies, enabling them to concentrate on their core activities.

Furthermore, thanks to the critical mass of skills and technologies made available to them, they will be assured of obtaining targets in their native conformation, thus guaranteeing the success of their programs for developing new drugs, vaccines and therapeutic antibodies.

Membrane proteins account for over 70 per cent of current therapeutic targets.

They are essential in discovering new drugs for the majority of the pathologies for which treatments are needed today: cancer, infectious diseases, neurodegenerative, metabolic and genetic diseases and so on.

As of now, however, there are fewer than ten companies specialized in this field around the world and, according to Calixar and Synthelis, none offers such a comprehensive and innovative range of services as their new alliance does.

The agreement provides for Synthelis to utilize its molecular biology know-how, deployed in multi-expression-systems and functional characterization configuration, to underpin the production phase.

Calixar will be responsible for the possible upstream identification and subsequent isolation, purification, stabilization and crystallization of targeted membrane proteins.

Calixar’s technology has already been validated in some 20 targets (including GPCR receptors, ionic channels, transporters and viral proteins) and its unique approach makes it possible to preserve the native conformation of membrane proteins in solution after their extraction and purification from any biological system.

Alongside Calixar’s results, Synthelis has validated its technology on more than 50 membrane targets.

The production processes it has developed are also known to avoid the denaturization of membrane proteins while ensuring they have a high level of expression and activity.

Moreover, Synthelis can produce large quantities (several mg) in two to three months, whereas traditional processes take up to a year.

“We have been undertaking joint R&D programs since the end of 2011, which has confirmed that our two companies have very complementary expertise,” said the president and co-founder of Calixar, Emmanuel Dejean.

Dejean continued, “We now want our customers to benefit from this critical mass of know-how and technology, which no other company currently offers in Europe.”

“Through this alliance, the two companies are strengthening every aspect of their business, not only their commercial clout, technical expertise and visibility but also their ability to innovate in their quest to find answers to complex sets of problems with great potential,” said the president and co-founder of Synthelis, Bruno Tillier. “This partnership also has an impact on the research structure in the Lyon-Grenoble area as the two companies are based in the region.”

The companies are going to undertake joint marketing campaigns to promote their product offer. Outside Europe, they also aim to get themselves known in North America and Asia.   


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Calixar, Aston University Announce Multidrug Resistance Collaboration
Purpose is to study the extraction, stabilization and crystallization of full-length human ABC transporters involved in multidrug resistance.
Wednesday, October 22, 2014
Scientific News
Crouching Protein, Hidden Enzyme
A new study led by scientists at The Scripps Research Institute (TSRI) and the University of California (UC), Berkeley shows how a crucial molecular enzyme starts in a tucked-in somersault position and flips out when it encounters the right target.
Spotlight on Acoustic Liquid Handling
Journal of Laboratory Automation special issue highlights how acoustic liquid handling enables breakthrough innovations.
3D Images of Enzymes May Lead to Improved Antibiotics
Research advances understanding of how crucial proteins function.
Supply Chain
Chemists discover how a single enzyme maintains a cell’s pool of DNA building blocks.
Seeing DROSHA for the First Time
IBS team gets the first glimpse of elusive protein structure.
Scientists Blueprint Tiny Cellular ‘Nanomachine’
Scientists have drawn up molecular blueprints of a tiny cellular ‘nanomachine’, whose evolution is an extraordinary feat of nature, by using one of the brightest X-ray sources on Earth.
Pioneering Brain Cancer Technique Could Lead to Better Prognosis for Patients
4,000th paper published from Diamond research could improve outcomes for brain cancer sufferers.
Big Moves in Protein Structure Prediction and Design
Custom design with atomic level accuracy enables researchers to craft a whole new world of proteins.
Pushing Drug Discovery Forward
A new study, led by scientists at The Scripps Research Institute (TSRI), shows how different pharmaceutical drugs hit either the “on” or “off” switch of a signaling protein linked to asthma, obesity and type 2 diabetes.
Solved Structure of S. pneumoniae Enzyme Could Lead to New Antibiotics
Scientists solve structure of a key bacterial enzyme from streptococcus pneumoniae: a major cause of bacterial meningitis, bronchitis, ear infection and pneumonia.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!